Publication | Closed Access

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Real-world SettingMedicinePathologyFirst-line TreatmentMolecular OncologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerCancer Research